Cancer Family
Myomatous Neoplasm
CI-CAN-00000282Explore in graph →
Non-malignant151 active trials1 approved drugs38 evidence items
- NCIt
- C214799
Loading cancer entity…
Cancer Family
CI-CAN-00000282Explore in graph →
Clinical trials
755 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06721689 | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors(PEEL-224) | recruiting | Phase 1 / Phase 2 | 59 | Theodore LaetschOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03400826 | Effects of Simvastatin on Uterine Leiomyoma Size | active not recruiting | Phase 2 | 60 | Johns Hopkins UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04299113 |
| Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma |
| active not recruiting |
| Phase 1 |
| 14 |
| Jonsson Comprehensive Cancer CenterOTHER |
| 1 |
| Jul 17, 2026 |
| clinicaltrials |
| NCT04624178 | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT06796543 | Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma(TARGET-RT) | recruiting | N/A | 70 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04925089 | Localized Leiomyosarcoma Biomarker Protocol | recruiting | — | 40 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05653388 | Metastatic Leiomyosarcoma Biomarker Protocol | recruiting | — | 200 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT07664956 | Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy | not yet recruiting | Phase 4 | 36 | Christiana Care Health ServicesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06088290 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)(SaLuDo) | active not recruiting | Phase 3 | 469 | PharmaMarINDUSTRY | 12 | Jun 18, 2026 | clinicaltrials |
| NCT06571734 | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma | recruiting | Phase 2 | 73 | Northwestern UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01871766 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | active not recruiting | Phase 2 | 115 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03050268 | Familial Investigations of Childhood Cancer Predisposition(SJFAMILY) | recruiting | — | 1,500 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06023641 | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | recruiting | Phase 2 | 135 | St. Jude Children's Research HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT06957431 | Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | recruiting | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04796012 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07120945 | Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)(Embrace Gyn) | active not recruiting | N/A | 70 | Medtronic - MITGINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07286188 | Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | recruiting | Phase 4 | 40 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06153667 | Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)(BETTER-UAE) | recruiting | — | 100 | Merit Medical Systems, Inc.INDUSTRY | 3 | May 29, 2026 | clinicaltrials |
| NCT06430320 | Ascertaining Longterm Outcomes of Fibroid Treatments(ALOFT) | active not recruiting | — | 700 | Henry Ford Health SystemOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT07182045 | Impact of Uterine and Ovarian Vessel Occlusion on Blood Loss in High Burden Minimally Invasive Myomectomy.(Myo-Bleed) | recruiting | N/A | 120 | The University of Texas Health Science Center, HoustonOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)(PerVision) | recruiting | Phase 1 / Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04200443 | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | active not recruiting | Phase 2 | 96 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07378098 | to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia | recruiting | Phase 3 | 254 | JW PharmaceuticalINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT03054792 | Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas | enrolling by invitation | Phase 1 | 18 | The Hospital for Sick ChildrenOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07173127 | The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters | recruiting | N/A | 30 | University Hospital, GenevaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02100904 | Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry(ULTRA Registry) | active not recruiting | — | 578 | University of California, San FranciscoOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 66 | National Cancer Institute LAOUNKNOWN | 2 | Apr 21, 2026 | clinicaltrials |
| NCT04308330 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies(NYMC195) | recruiting | Phase 1 | 30 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | not yet recruiting | N/A | 143 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06566092 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | active not recruiting | Phase 1 | 40 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07512973 | Single-channel Fibroid Morcellation System Used in Clinical Research on Laparoscopic Myomectomy | not yet recruiting | N/A | 78 | First People's Hospital of HangzhouOTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT07501676 | Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief(TUNES) | not yet recruiting | N/A | 60 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06692335 | HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids | recruiting | N/A | 112 | Chinese University of Hong KongOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04383119 | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma(ISG-ARTICLE) | recruiting | Phase 2 | 100 | Italian Sarcoma GroupNETWORK | 1 | Mar 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2026source: clinicaltrials